LOADING
Comparing Johnson & Johnson (JNJ) and AbbVie Inc (ABBV), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $555.2B | $355.4B |
| P/E Ratio | 26.7 | 84.8 |
| Forward P/E | 20.0 | 14.2 |
| PEG Ratio | 3.01 | 0.47 |
| EPS | $8.63 | $2.37 |
| Revenue Growth (YoY) | 9.9% | 10.0% |
| Profit Margin | 21.8% | 6.9% |
| Return on Equity | 35.0% | 62.3% |
| Dividend Yield | 2.30% | 3.32% |
| Beta | 0.33 | 0.36 |
| 52-Week High | $251.71 | $239.13 |
| 52-Week Low | $142.16 | $171.00 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. AbbVie Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.